Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer
AACR Annual Meeting 2021
Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response to therapy. Clinicians may be able to personalize dietary interventions to optimize patient care.
The ASCO Post Staff
Patrick M. Forde, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses results from the CheckMate 816 trial, which showed that adding nivolumab to chemotherapy as a neoadjuvant treatment for patients with resectable non–small cell lung cancer improved the pathologic complete response rate to 24%, compared to 2.2% with chemotherapy alone (Abstract CT003).
The ASCO Post Staff
Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the challenges in developing CAR T-cell therapy, as well as the progress being made, such as creating hybrid CAR and T-cell receptors that should enable T cells to recognize much lower levels of antigens. The field, he says, is poised to take on a range of solid tumors to extend the successes in hematologic malignancies.
The ASCO Post Staff
Carey K. Anders, MD, of the Duke Cancer Center, discusses the ways in which treatment of brain metastases arising from solid tumors has moved into a new era of patient care and how the field may advance.
The ASCO Post Staff
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, University of Sydney, discusses results of the CheckMate 915 trial, which may reinforce nivolumab as an adjuvant standard of care in patients with stage IIIB–D/IV melanoma, with or without complete lymphadenectomy (Abstract CT004).
The ASCO Post Staff
Dennis J. Slamon, MD, PhD, of the UCLA David Geffen School of Medicine, reflects on the ways in which breast cancer research pioneered the targeted treatment approach, as understanding of the basic biology of tumors deepened and new pathways were uncovered. He sees a future ripe with possibilities for new molecular targets to further improve outcomes for patients with breast cancer and other types of tumors.
